MAPK signaling is shown to be activated in prostate cancer, especially in later stages of the disease [41]–[43], and it was recently suggested that the MAPK signaling pathway may be a target for prostate cancer therapy, if it is inhibited simultaneously with other pathways, such as PI3K/AKT signaling [44]. This evidence concerns the gene AKT1 and prostate carcinoma.